Novel oral anticoagulants and trauma: The results of a prospective American Association for the Surgery of Trauma Multi-Institutional Trial: Kobayashi L, Barmparas G, Bosarge P, et al. J Trauma Acute Care Surg 2017; 82(5):827-835.

Abstract

Trauma remains one of the leading causes of death in the United States. Additionally, the number of elderly trauma patients taking oral antithrombotics (OATs), including warfarin antiplatelet agents and novel oral anticoagulants (NOAs), has been steadily increasing. While patients on warfarin have been found to have poor outcomes following trauma, particularly after intracranial hemorrhage (ICH), trauma outcomes in patients taking NOAs are unknown.